To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Cefadroxil monohydrate, USP is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemoly...
Cefadroxil monohydrate is acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy. Urinary Tract Infections : For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d....
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Cefadroxil monohydrate, USP is a semisynthetic cephalosporin antibiotic intended for oral administration. It is a white to yellowish-white crystalline powder. It is soluble in water and it is acid-stable. It is chemically designated as 5-Thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monohydrate, [6R-[6α,7β (R*)]]-. It has the formula C16H17N3O5S • H2O and the molecular weight of 381.40. It has the following structural formula:
Each 5 mL of reconstituted suspension for oral administration contains cefadroxil monohydrate equivalent to 125 mg, 250 mg or 500 mg of cefadroxil. In addition, cefadroxil for oral suspension contains the following inactive ingredients: colloidal silicon dioxide, FD&C yellow no. 6 aluminum lake, flavor fruit gum, flavor raspberry, polysorbate 80, sodium benzoate, sucrose, xanthan gum.
Cefadroxil monohydrate is rapidly absorbed after oral administration. Following single doses of 500 mg and 1000 mg, average peak serum concentrations were approximately 16 and 28 mcg/mL, respectively. Measurable levels were present 12 hours after administration. Over 90% of the drug is excreted unchanged in the urine within 24 hours. Peak urine concentrations are approximately 1800 mcg/mL during the period following a single 500 mg oral dose. Increases in dosage generally produce a proportionate increase in cefadroxil monohydrate urinary concentration. The urine antibiotic concentration, following a 1 g dose, was maintained well above the MIC of susceptible urinary pathogens for 20 to 22 hours.
In vitro tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cefadroxil has been shown to be active against the following organisms both in vitro and in clinical infections (see INDICATIONS AND USAGE):
Beta-hemolytic streptococci
Staphylococci, including penicillinase-producing strains
Streptococcus (Diplococcus) pneumoniae
Escherichia coli
Proteus mirabilis
Klebsiella species
Moraxella (Branhamella) catarrhalis
Note: Most strains of Enterococcus faecalis (formerly Streptococcus faecalis) and Enterococcus faecium (formerly Streptococcus faecium) are resistant to cefadroxil monohydrate. It is not active against most strains of Enterobacter species, Morganella morganii (formerly Proteus morganii), and P. vulgaris. It has no activity against Pseudomonas species and Acinetobacter calcoaceticus (formerly Mima and Herellea species).
Diffusion techniques
The use of antibiotic disk susceptibility test methods which measure zone diameter give an accurate estimation of antibiotic susceptibility. One such standard procedure1 which has been recommended for use with disks to test susceptibility of organisms to cefadroxil monohydrate uses the cephalosporin class (cephalothin) disk. Interpretation involves the correlation of the diameters obtained in the disk test with the minimum inhibitory concentration (MIC) for cefadroxil.
Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30 mcg cephalothin disk should be interpreted according to the following criteria:
Interpretive Criteria for Enterobacteriaceae and Staphylococcus spp.
| Zone Diameter (mm) | Interpretation |
| ≥ 18 | (S) Susceptible |
| 15 to 17 | (I) Intermediate |
| ≤ 14 | (R) Resistant |
A report of "Susceptible" indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of "intermediate susceptibility" suggests that the organism would be susceptible if high dosage is used or if the infection is confined to tissue and fluids (e.g., urine) in which high antibiotic levels are attained. A report of "Resistant" indicates that achievable concentrations of the antibiotic are unlikely to be inhibitory and other therapy should be selected.
Standardized procedures require the use of laboratory control organisms. The 30 mcg cephalothin disk should give the following zone diameters:
| Organism | Zone Diameter (mm) |
| Staphylococcus aureus ATCC 25923 | 29 to 37 |
| Escherichia coli ATCC 25922 | 15 to 21 |
Dilution Techniques
When using the NCCLS agar dilution or broth dilution (including microdilution) method2 or equivalent, a bacterial isolate may be considered susceptible if the MIC (minimum inhibitory concentration) value for cephalothin is 8 mcg/mL or less. Organisms are considered resistant if the MIC is 32 mcg/mL or greater. Organisms with an MIC value of less than 32 mcg/mL but greater than 8 mcg/mL are intermediate.
| MIC (mcg/mL) | Interpretation |
| ≤ 8 | (S) Susceptible |
| 16 | (I) Intermediate |
| ≥ 32 | (R) Resistant |
As with standard diffusion methods, dilution procedures require the use of laboratory control organisms. Standard cephalothin powder should give MIC values in the range of 0.12 mcg/mL and 0.5 mcg/mL for Staphylococcus aureus ATCC 29213. For Escherichia coli ATCC 25922, the MIC range should be between 4 mcg/mL and 16 mcg/mL.
Cefadroxil monohydrate, USP is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases:
Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species.
Skin and skin structure infections caused by staphylococci and/or streptococci.
Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci).
Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available.
Note: Culture and susceptibility tests should be initiated prior to and during therapy.
Renal function studies should be performed when indicated.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Cefadroxil monohydrate is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
BEFORE THERAPY WITH CEFADROXIL MONOHYDRATE IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFADROXIL, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.
IF AN ALLERGIC REACTION TO CEFADROXIL MONOHYDRATE OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefadroxil for oral suspension, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C.difficile.
C.difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C.difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C.difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.difficile, and surgical evaluation should be instituted as clinically indicated.
Cefadroxil monohydrate should be used with caution in the presence of markedly impaired renal function (creatinine clearance rate of less than 50 mL/min/1.73 M2). (See DOSAGE AND ADMINISTRATION.) In patients with known or suspected renal impairment, careful clinical observation and appropriate laboratory studies should be made prior to and during therapy.
Prescribing cefadroxil for oral suspension in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Prolonged use of cefadroxil monohydrate may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Cefadroxil monohydrate should be prescribed with caution in individuals with history of gastrointestinal disease, particularly colitis.
Patients should be counseled that antibacterial drugs including cefadroxil for oral suspension should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefadroxil for oral suspension is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefadroxil for oral suspension or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever)even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Positive direct Coombs’ tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs’ testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs’ test may be due to the drug.
No long-term studies have been performed to determine carcinogenic potential. No genetic toxicity tests have been performed.
Pregnancy Category B
Reproduction studies have been performed in mice and rats at doses up to 11 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefadroxil monohydrate. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Cefadroxil monohydrate has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.
Caution should be exercised when cefadroxil monohydrate is administered to a nursing mother.
(See DOSAGE AND ADMINISTRATION.)
Of approximately 650 patients who received cefadroxil for the treatment of urinary tract infections in three clinical trials, 28% were 60 years and older, while 16% were 70 years and older. Of approximately 1000 patients who received cefadroxil for the treatment of skin and skin structure infection in 14 clinical trials, 12% were 60 years and older while 4% were 70 years and over. No overall differences in safety were observed between the elderly patients in these studies and younger patients. Clinical studies of cefadroxil for the treatment for pharyngitis or tonsillitis did not include sufficient number of patients 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience with cefadroxil has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Cefadroxil is substantially excreted by the kidney, and dosage adjustment is indicated for patients with renal impairment (see DOSAGE AND ADMINISTRATION: Renal Impairment). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Gastrointestinal
Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS). Dyspepsia, nausea and vomiting have been reported rarely. Diarrhea has also occurred.
Hypersensitivity
Allergies (in the form of rash, urticaria, angioedema, and pruritus) have been observed. These reactions usually subsided upon discontinuation of the drug. Anaphylaxis has also been reported.
Other
Other reactions have included hepatic dysfunction including cholestasis and elevations in serum transaminase, genital pruritus, genital moniliasis, vaginitis, moderate transient neutropenia, fever. Agranulocytosis, thrombocytopenia, idiosyncratic hepatic failure, erythema multiforme, Stevens-Johnson syndrome, serum sickness, and arthralgia have been rarely reported.
In addition to the adverse reactions listed above which have been observed in patients treated with cefadroxil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:
Toxic epidermal necrolysis, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, positive Coombs’ test, increased BUN, increased creatinine, elevated alkaline phosphatase, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated bilirubin, elevated LDH, eosinophilia, pancytopenia, neutropenia.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced (see DOSAGE AND ADMINISTRATION and OVERDOSAGE). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
A study of children under six years of age suggested that ingestion of less than 250 mg/kg of cephalosporins is not associated with significant outcomes. No action is required other than general support and observation. For amounts greater than 250 mg/kg, induce gastric emptying.
In five anuric patients, it was demonstrated that an average of 63% of a 1 g oral dose is extracted from the body during a 6 to 8 hour hemodialysis session.
Cefadroxil monohydrate is acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy.
Urinary Tract Infections: For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.).
For all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.).
Skin and Skin Structure Infections: For skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.).
Pharyngitis and Tonsillitis: Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis — 1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days.
For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of cefadroxil monohydrate should be administered for at least 10 days.
| See chart for total daily dosage for children. | ||||
| DAILY DOSAGE OF CEFADROXIL FOR ORAL SUSPENSION | ||||
| Child’s Weight | ||||
| lbs | kg | 125 mg/5mL | 250 mg/5mL | 500mg/5mL |
| 10 | 4.5 | 1 tsp | ½ tsp | |
| 20 | 9.1 | 2 tsp | 1 tsp | |
| 30 | 13.6 | 3 tsp | 1 ½ tsp | |
| 40 | 18.2 | 4 tsp | 2 tsp | 1 tsp |
| 50 | 22.7 | 5 tsp | 2 ½ tsp | 1 ¼ tsp |
| 60 | 27.3 | 6 tsp | 3 tsp | 1 ½ tsp |
| 70 & above | 31.8+ | — | — | 2 tsp |
In patients with renal impairment, the dosage of cefadroxil monohydrate should be adjusted according to creatinine clearance rates to prevent drug accumulation. The following schedule is suggested. In adults, the initial dose is 1000 mg of cefadroxil monohydrate and the maintenance dose (based on the creatinine clearance rate [mL/min/1.73 M2]) is 500 mg at the time intervals listed below.
| Creatinine Clearances | Dosage Interval |
| 0 to 10 mL/min | 36 hours |
| 10 to 25 mL/min | 24 hours |
| 25 to 50 mL/min | 12 hours |
Patients with creatinine clearance rates over 50 mL/min may be treated as if they were patients having normal renal function.
Reconstitution Directions for Oral Suspension
| Bottle Size | Reconstitution Directions |
| 100 mL | Suspend in a total of 70mL of water. Method: Tap bottle lightly to loosen powder. Add 70 mL of water in two portions. Shake well after each addition. |
| 75 mL | Suspend in a total of 53 mL of water. Method: Tap bottle lightly to loosen powder. Add 53 mL of water in two portions. Shake well after each addition. |
| 50 mL | Suspend in a total of 35 mL of water. Method: Tap bottle lightly to loosen powder. Add 35 mL of water in two portions. Shake well after each addition. |
| After reconstitution, store in refrigerator. Shake well before using. Keep container tightly closed. Discard unused portion after 14 days. | |
Cefadroxil For Oral Suspension, USP is available in:
The 125 mg per 5 mL of reconstituted suspension* contains cefadroxil monohydrate equivalent to 125 mg with a light orange colored powder forming orange suspension on constitution with water. The resulting suspension has a characteristic mixed fruit flavor and is available as follows:
NDC 63304-972-04 100 mL bottles
The 250 mg per 5 mL of reconstituted suspension* contains cefadroxil monohydrate equivalent to 250 mg with a light orange colored powder forming orange suspension on constitution with water. The resulting suspension has a characteristic mixed fruit flavor and is available as follows:
NDC 63304-973-03 50 mL bottles
NDC 63304-973-04 100 mL bottles
The 500 mg per 5 mL of reconstituted suspension* contains cefadroxil monohydrate equivalent to 500 mg with a light orange colored powder forming orange suspension on constitution with water. The resulting suspension has a characteristic mixed fruit flavor and is available as follows:
NDC 63304-974-01 75 mL bottles
NDC 63304-974-04 100 mL bottles
*SHAKE ORAL SUSPENSION WELL BEFORE USING. Keep bottle tightly closed. After reconstitution, store in refrigerator. Any unused portion of the reconstituted suspension must be discarded after 14 days.
Prior to reconstitution: Store at 20 - 25° C (68 - 77° F). (See USP Controlled Room Temperature).
1. Clinical and Laboratory Standards Institute, Approved Standard, Performance Standards for Antimicrobial Disk Susceptibility Test, 11th Edition, Vol. 32 (1): M02-A11, Wayne, PA, January, 2012.
2. Clinical and Laboratory Standards Institute, Approved Standard: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 9th Edition, Vol. 32 (2): M07-A9, Wayne, PA, January, 2012.
Manufactured for:
Ranbaxy Pharmaceuticals Inc.
Jacksonville, FL 32257 USA
by: Ranbaxy Laboratories Limited
New Delhi – 110 019, India
August 2012 S-04
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 309048 | cefadroxil 250 MG in 5 mL Oral Suspension | PSN | 2 |
| 105171 | cefadroxil 500 MG in 5 mL Oral Suspension | PSN | 2 |
| 105171 | cefadroxil 100 MG/ML Oral Suspension | SCD | 2 |
| 105170 | cefadroxil 25 MG/ML Oral Suspension | SCD | 2 |
| 309048 | cefadroxil 50 MG/ML Oral Suspension | SCD | 2 |
| 105171 | cefadroxil (as cefadroxil monohydrate) 100 MG/ML Oral Suspension | SY | 2 |
| 105170 | cefadroxil (as cefadroxil monohydrate) 25 MG/ML Oral Suspension | SY | 2 |
| 309048 | cefadroxil (as cefadroxil monohydrate) 50 MG/ML Oral Suspension | SY | 2 |
| 105170 | cefadroxil 125 MG per 5 ML Oral Suspension | SY | 2 |
| 309048 | cefadroxil 250 MG per 5 ML Powder for Oral Suspension | SY | 2 |
| 105171 | cefadroxil 500 MG per 5 ML Powder for Oral Suspension | SY | 2 |
| Class | Version | Type | Effective |
|---|---|---|---|
| CEFADROXIL ANHYDROUS Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 560bed03-0257-a1db-0638-2c46fc35054c | Product name | 2 | 20170824 |
| 34f1b9ee-0673-df8c-ddae-36eaf4c48382 | Product name | 1 | 20140508 |
| 3793572a-4958-68b2-f923-8cf695ec1cc1 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 63304-972-04 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d2a7-cd31-e053-dbdaa90ab51a | CEFADROXIL FOR ORAL SUSPENSION, USP Rx only |
| 63304-973-03 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d2a7-cd31-e053-dbdaa90ab51a | CEFADROXIL FOR ORAL SUSPENSION, USP Rx only |
| 63304-973-04 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d2a7-cd31-e053-dbdaa90ab51a | CEFADROXIL FOR ORAL SUSPENSION, USP Rx only |
| 63304-974-01 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d2a7-cd31-e053-dbdaa90ab51a | CEFADROXIL FOR ORAL SUSPENSION, USP Rx only |
| 63304-974-04 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d2a7-cd31-e053-dbdaa90ab51a | CEFADROXIL FOR ORAL SUSPENSION, USP Rx only |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63304-972-04 | CEFADROXIL | 100 mL in 1 BOTTLE | POWDER, FOR SUSPENSION | 100 | 2 | |
| 63304-973-03 | CEFADROXIL | 50 mL in 1 BOTTLE | POWDER, FOR SUSPENSION | 50 | 2 | |
| 63304-973-04 | CEFADROXIL | 100 mL in 1 BOTTLE | POWDER, FOR SUSPENSION | 100 | 2 | |
| 63304-974-01 | CEFADROXIL | 75 mL in 1 BOTTLE | POWDER, FOR SUSPENSION | 75 | 2 | |
| 63304-974-04 | CEFADROXIL | 100 mL in 1 BOTTLE | POWDER, FOR SUSPENSION | 100 | 2 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63304-972 | CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.] | 2 | 1 package rows | 20130321_5fc4f89c-cf94-4e7a-bf31-d3d86a242efa.zip |
| 63304-973 | CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.] | 2 | Legacy NDC, 2 package rows | 20130321_5fc4f89c-cf94-4e7a-bf31-d3d86a242efa.zip |
| 63304-974 | CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.] | 2 | Legacy NDC, 2 package rows | 20130321_5fc4f89c-cf94-4e7a-bf31-d3d86a242efa.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63304-973-04 | ML - Milliliter | 63304-973 | 4989c659-971d-44e0-ba00-0a0f8d17568c | 1 | 2013-02-13 |
| 63304-974-01 | ML - Milliliter | 63304-974 | e187cda9-4fb4-4516-bc0f-8f09dc215240 | 1 | 2013-02-13 |
| 63304-974-04 | ML - Milliliter | 63304-974 | 6d30c130-0ac2-4735-8fc2-c01e9217b7dd | 1 | 2013-02-13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CEFADROXIL | ACTIVE INGREDIENT | 280111G160 | 2 | |
| CEFADROXIL ANHYDROUS | ACTIVE MOIETY | Q525PA8JJB | 2 | |
| FD&C YELLOW NO. 6 | INACTIVE INGREDIENT | H77VEI93A8 | 2 | |
| FRUIT | INACTIVE INGREDIENT | C2AIY4ERZC | 2 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 2 | |
| RASPBERRY | INACTIVE INGREDIENT | 4N14V5R27W | 2 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 63304-972 | 63304-972-04 |
| 63304-973 | 63304-973-03, 63304-973-04 |
| 63304-974 | 63304-974-01, 63304-974-04 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CEFADROXIL | 280111G160 | ACTIM |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| FD&C YELLOW NO. 6 | H77VEI93A8 | IACT |
| FRUIT | C2AIY4ERZC | IACT |
| RASPBERRY | 4N14V5R27W | IACT |
| POLYSORBATE 80 | 6OZP39ZG8H | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| SUCROSE | C151H8M554 | IACT |
| XANTHAN GUM | TTV12P4NEE | IACT |
| CEFADROXIL | 280111G160 | ACTIM |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| FD&C YELLOW NO. 6 | H77VEI93A8 | IACT |
| FRUIT | C2AIY4ERZC | IACT |
| RASPBERRY | 4N14V5R27W | IACT |
| POLYSORBATE 80 | 6OZP39ZG8H | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| SUCROSE | C151H8M554 | IACT |
| XANTHAN GUM | TTV12P4NEE | IACT |
| CEFADROXIL | 280111G160 | ACTIM |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| FD&C YELLOW NO. 6 | H77VEI93A8 | IACT |
| FRUIT | C2AIY4ERZC | IACT |
| RASPBERRY | 4N14V5R27W | IACT |
| POLYSORBATE 80 | 6OZP39ZG8H | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| SUCROSE | C151H8M554 | IACT |
| XANTHAN GUM | TTV12P4NEE | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SPRAY / NASAL | 0.01 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, EXTENDED RELEASE / ORAL | 528 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, FILM COATED / ORAL | 0.08 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | LOTION / TOPICAL | 0.3 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION/ DROPS / ORAL | 23 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SOLUTION / ORAL | 280 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION / ORAL | 450 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | TABLET, COATED / ORAL | 0.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, ORALLY DISINTEGRATING / ORAL | 0.15 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER / ORAL | 275 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TAMPON / VAGINAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | EMULSION / OPHTHALMIC | 26 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SUSPENSION / TOPICAL | 0.11 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | CAPSULE, EXTENDED RELEASE / ORAL | 4.59 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAVENOUS | 0.5 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SUSPENSION / ORAL | 600 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SOLUTION / OPHTHALMIC | 0.6 %w/v | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION, EMULSION / INTRAVENOUS | 0.1 %w/v | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 36 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION/ DROPS / OPHTHALMIC | 0.25 %w/v | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | TABLET / SUBLINGUAL | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | TABLET / BUCCAL | 1 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SOLUTION / ORAL | 10 mg/5ml | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | ENEMA / RECTAL | 0.01 %w/v | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | FILM / SUBLINGUAL | 0.03 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAVENOUS | 1170 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 2350 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION / INTRAMUSCULAR | 864 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | LOZENGE / ORAL | 1264 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | SOLUTION / ORAL | 75.3 mg/15ml | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | SUSPENSION, EXTENDED RELEASE / ORAL | 0.12 mg/5ml | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | CONCENTRATE / ORAL | 1 mg/1ml | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 53 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAVITREAL | 0.02 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FOR SUSPENSION / ORAL | 220 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| FD&C YELLOW NO. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | CAPSULE, COATED PELLETS / ORAL | NA |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A065115-001 | CEFADROXIL | CEFADROXIL/CEFADROXIL HEMIHYDRATE | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | ||
| A065115-002 | CEFADROXIL | CEFADROXIL/CEFADROXIL HEMIHYDRATE | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | ||
| A065115-003 | CEFADROXIL | CEFADROXIL/CEFADROXIL HEMIHYDRATE | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A065115-002 | CEFADROXIL | EQ 250MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A065115-003 | CEFADROXIL | EQ 500MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A065115-001 | CEFADROXIL | EQ 125MG BASE/5ML | FOR SUSPENSION / ORAL | 2003-03-26 | 301d65b070ca… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a95b07d7-65c1-438d-91e0-0eaca684eccf | 5fc4f89c-cf94-4e7a-bf31-d3d86a242efa | 2013-08-14 | Boxed warning, Warnings, Adverse reactions | a95b07d7-65c1-438d-91e0-0eaca684eccf 5fc4f89c-cf94-4e7a-bf31-d3d86a242efa |
Adverse event summaries are temporarily unavailable. Other product information remains available.